RecallDepth
Class II Terminated

Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0703-1995-01.

Company
Teva Pharmaceuticals Usa
Recall Initiated
February 10, 2021
Posted
March 3, 2021
Recall Number
D-0280-2021
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
12,609 vials
Firm Location
Parsippany, NJ, United States

Reason for Recall

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Distribution

Product was distributed nationwide in the USA and Puerto Rico.

Lot / Code Info

Lot # 31326456B, exp. date 02/28/2021

More recalls by Teva Pharmaceuticals Usa

View all recalls by this company →

Other recent Class II Drug recalls